Regenxbio Ebit from 2010 to 2025

RGNX Stock  USD 6.54  0.06  0.91%   
Regenxbio EBIT yearly trend continues to be fairly stable with very little volatility. EBIT is likely to outpace its year average in 2025. During the period from 2010 to 2025, Regenxbio EBIT regression line of annual values had r-squared of  0.37 and arithmetic mean of (73,398,308). View All Fundamentals
 
EBIT  
First Reported
2013-12-31
Previous Quarter
-52.5 M
Current Value
-58.8 M
Quarterly Volatility
61.8 M
 
Yuan Drop
 
Covid
Check Regenxbio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenxbio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 20.9 M, Interest Expense of 7.5 M or Selling General Administrative of 106.9 M, as well as many indicators such as Price To Sales Ratio of 9.5, Dividend Yield of 0.0 or PTB Ratio of 2.38. Regenxbio financial statements analysis is a perfect complement when working with Regenxbio Valuation or Volatility modules.
  
Check out the analysis of Regenxbio Correlation against competitors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Latest Regenxbio's Ebit Growth Pattern

Below is the plot of the Ebit of Regenxbio over the last few years. It is Regenxbio's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regenxbio's overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
-149.0M-105.2M160.0M-257.2M-256.8M-231.1M-219.6M100%
       Timeline  

Regenxbio Ebit Regression Statistics

Arithmetic Mean(73,398,308)
Geometric Mean43,298,495
Coefficient Of Variation(166.42)
Mean Deviation98,290,846
Median(23,160,000)
Standard Deviation122,148,417
Sample Variance14920.2T
Range417.1M
R-Value(0.61)
Mean Square Error10123.9T
R-Squared0.37
Significance0.01
Slope(15,536,416)
Total Sum of Squares223803.5T

Regenxbio Ebit History

2025-219.6 M
2024-231.1 M
2023-256.8 M
2022-257.2 M
2021160 M
2020-105.2 M
2019-149 M

Other Fundumenentals of Regenxbio

About Regenxbio Financial Statements

Regenxbio investors use historical fundamental indicators, such as Regenxbio's Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Regenxbio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBIT-231.1 M-219.6 M
EBITDA-215.5 M-204.7 M
Ebt Per Ebit 1.13  1.08 
Ebit Per Revenue(2.67)(2.81)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.

Trending Assets

PTGX
Protagonist Therapeutics
36.34  0.19  0.53 
DAWN
Day One Biopharmaceu
9.87  -1.95  -16.5 
QURE
Uniqure NV
12.07  0.40  3.43 
GLUE
Monte Rosa Therapeutics
5.45  -0.33  -5.71 
News Freq…Investor S…